166 related articles for article (PubMed ID: 36371226)
1. Phase 1 study of intraventricular
Kramer K; Pandit-Taskar N; Kushner BH; Zanzonico P; Humm JL; Tomlinson U; Donzelli M; Wolden SL; Haque S; Dunkel I; Souweidane MM; Greenfield JP; Tickoo S; Lewis JS; Lyashchenko SK; Carrasquillo JA; Chu B; Horan C; Larson SM; Cheung NV; Modak S
J Hematol Oncol; 2022 Nov; 15(1):165. PubMed ID: 36371226
[TBL] [Abstract][Full Text] [Related]
2. Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy.
Kramer K; Donzelli MA; Pessin MS
Cancer Immunol Immunother; 2021 Aug; 70(8):2411-2414. PubMed ID: 33533945
[TBL] [Abstract][Full Text] [Related]
3. B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study.
Modak S; Zanzonico P; Grkovski M; Slotkin EK; Carrasquillo JA; Lyashchenko SK; Lewis JS; Cheung IY; Heaton T; LaQuaglia MP; Cheung NV; Pandit-Taskar N
J Clin Oncol; 2020 Dec; 38(36):4283-4291. PubMed ID: 33119478
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and Dosimetry of Intraventricularly Administered
Pandit-Taskar N; Zanzonico PB; Kramer K; Grkovski M; Fung EK; Shi W; Zhang Z; Lyashchenko SK; Fung AM; Pentlow KS; Carrasquillo JA; Lewis JS; Larson SM; Cheung NV; Humm JL
J Nucl Med; 2019 Dec; 60(12):1794-1801. PubMed ID: 31405921
[TBL] [Abstract][Full Text] [Related]
5. Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes.
Bailey K; Pandit-Taskar N; Humm JL; Zanzonico P; Gilheeney S; Cheung NV; Kramer K
J Neurooncol; 2019 May; 143(1):101-106. PubMed ID: 30879172
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunoscintigraphy and Pretreatment Dosimetry of
Pandit-Taskar N; Grkovski M; Zanzonico PB; Pentlow KS; Modak S; Kramer K; Humm JL
J Nucl Med; 2023 Jun; 64(6):946-950. PubMed ID: 36759197
[TBL] [Abstract][Full Text] [Related]
7. IntraOmmaya compartmental radioimmunotherapy using
Yerrabelli RS; He P; Fung EK; Kramer K; Zanzonico PB; Humm JL; Guo H; Pandit-Taskar N; Larson SM; Cheung NV
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1166-1177. PubMed ID: 33047248
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and Radiation Dosimetry of Intraperitoneally Administered
Grkovski M; Modak S; Zanzonico PB; Carrasquillo JA; Larson SM; Humm JL; Pandit-Taskar N
J Nucl Med; 2022 Jul; 63(7):1094-1100. PubMed ID: 34857661
[TBL] [Abstract][Full Text] [Related]
9. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.
Kramer K; Kushner BH; Modak S; Pandit-Taskar N; Smith-Jones P; Zanzonico P; Humm JL; Xu H; Wolden SL; Souweidane MM; Larson SM; Cheung NK
J Neurooncol; 2010 May; 97(3):409-18. PubMed ID: 19890606
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.
Kramer K; Humm JL; Souweidane MM; Zanzonico PB; Dunkel IJ; Gerald WL; Khakoo Y; Yeh SD; Yeung HW; Finn RD; Wolden SL; Larson SM; Cheung NK
J Clin Oncol; 2007 Dec; 25(34):5465-70. PubMed ID: 18048828
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of radioimmunotherapy with intraventricular
Kramer K; Pandit-Taskar N; Humm JL; Zanzonico PB; Haque S; Dunkel IJ; Wolden SL; Donzelli M; Goldman DA; Lewis JS; Lyashchenko SK; Khakoo Y; Carrasquillo JA; Souweidane MM; Greenfield JP; Lyden D; De Braganca KD; Gilheeney SW; Larson SM; Cheung NV
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28940863
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma.
Tringale KR; Wolden SL; Casey DL; Kushner BH; Luo L; Pandit-Taskar N; Souweidane M; Cheung NV; Modak S; Basu EM; Kramer K
Pediatr Blood Cancer; 2023 Feb; 70(2):e30075. PubMed ID: 36349892
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with 131I-omburtamab for leptomeningeal disease.
Prasad K; Serencsits BE; Chu BP; Dauer LT; Donzelli M; Basu E; Kramer K; Pandit-Taskar N
Res Sq; 2024 Feb; ():. PubMed ID: 38464207
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma.
Tringale KR; Wolden SL; Karajannis M; Haque S; Pasquini L; Yildirim O; Rosenblum M; Benhamida JK; Cheung NK; Souweidane M; Basu EM; Pandit-Taskar N; Zanzonico PB; Humm JL; Kramer K
J Neurooncol; 2023 Mar; 162(1):69-78. PubMed ID: 36853490
[TBL] [Abstract][Full Text] [Related]
16.
Zhang Y; Kupferschlaeger J; Lang P; Reischl G; Handgretinger RJ; Fougère C; Dittmann H
J Nucl Med; 2022 Feb; 63(2):205-211. PubMed ID: 34049985
[TBL] [Abstract][Full Text] [Related]
17. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
[TBL] [Abstract][Full Text] [Related]
18. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies.
Kramer K; Smith M; Souweidane MM
Pediatr Blood Cancer; 2014 Sep; 61(9):1590-2. PubMed ID: 24777835
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
